Clinical Trial Solutions ("CTS") ●Tigermed Segment Revenue (RMB mm) 2,172.1 1H2022 -3.2% 2,103.4 Segment Gross Profit and Margin (RMB mm) 36.9% +3.1% 39.2% 800.7 825.5 1H2023 1H2022 1H2023 6

View entire presentation